Clinical trial

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

NCT00030667

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record imatinib mesylate Normalized identity: imatinib mesylateView linked drug · Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention laboratory biomarker analysis Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention pharmacological study Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2002-05-01

PhasePHASE2

Conditions

Childhood Desmoplastic Small Round Cell Tumorunresolved

Childhood Synovial Sarcomaunresolved

Gastrointestinal Stromal Tumorverified · MONDO: gastrointestinal stromal tumor

Lung Metastasesunresolved

Recurrent Childhood Soft Tissue Sarcomaunresolved

Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumorunresolved

Recurrent Neuroblastomaunresolved

Recurrent Osteosarcomaunresolved

Interventions

imatinib mesylateDRUG · verified · RxNorm: imatinib mesylate

laboratory biomarker analysisOTHER

pharmacological studyOTHER

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00030667 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.